Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Targeting the MYC oncogene with a selective bi-steric mTORC1 inhibitor elicits tumor regression in MYC-driven cancers

Cell chemical biology(2025)10.1016/j.chembiol.2025.07.004Source: DataRank Database

Targeting the MYC oncogene with a selective bi-steric mTORC1 inhibitor elicits tumor regression in MYC-driven cancers is a research paper published in Cell chemical biology (2025). On theSindex it has a DataRank of 0. It has been cited 6 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

6 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (9 grants)Impact (FWCI 2.38)OA: closedTopics (60)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (20)

Yu Chi Yang ORCID,Ian Lai ORCID,Jangho Park ORCID,Lilian Yao,James W. Evans ORCID

Live enrichment

PubMed:40803322 OpenAlex:https://openalex.org/W4413102818

National Institutes of Health

Grant: RO1CA208735

National Institutes of Health

Grant: R01CA188383

National Institutes of Health

Grant: R35CA25318

National Institutes of Health

Grant: U01CA288433

National Institutes of Health

Grant: RO1CA184384

National Institutes of Health

Grant: RO1CA253180

National Heart Lung and Blood Institute Division of Intramural Research

Grant: T32HL120824

NCI NIH HHS

Grant: R01 CA208735

Revolution Medicines Inc

FWCI

2.38

Citation Percentile

0.9%

Citation Trend

2026

closedLicense: http://www.elsevier.com/open-access/userlicense/1.0/

publisherhttps://api.elsevier.com/content/article/PII:S2451945625002272?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2451945625002272?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.chembiol.2025.07.004

repositoryhttps://pubmed.ncbi.nlm.nih.gov/40803322

Fields of Study

PI3K/AKT/mTOR signaling in cancerProtein Degradation and InhibitorsCancer Mechanisms and TherapyMechanistic Target of Rapamycin Complex 1HumansAnimalsProto-Oncogene Proteins c-mycMiceAntineoplastic AgentsCell ProliferationCell Line, TumorNeoplasmsMice, NudeDrug Screening Assays, AntitumorFemaleXenograft Model Antitumor Assays

MeSH Terms

Mechanistic Target of Rapamycin Complex 1AnimalsAntineoplastic AgentsDrug Screening Assays, AntitumorFemaleHumansMice, NudeNeoplasmsProto-Oncogene Proteins c-mycXenograft Model Antitumor AssaysCell Line, TumorCell ProliferationMice

Keywords

mTORC1Cancer researchOncogeneProto-Oncogene Proteins c-mycRegressionSteric effectsBiologyCancerMedicineOncologyGeneChemistryInternal medicineGeneticsRegulation of gene expressionPsychologyCell cycleSignal transductionPI3K/AKT/mTOR pathwayStereochemistryHepatocellular carcinomaMYCHCCImmune ActivationTumor Regression4Ebp1S6kImmune Checkpoint BlockadeTumor Immune MicroenvironmentMyc-driven CancersMtorc1-selective Inhibitors

Sustainable Development Goals

SDG 0: Good health and well-being

Targeting the MYC oncogene with a selective bi-steric mTORC1 inhibitor elicits tumor regression in MYC-driven cancers

FAIR Checklist

Authors (20)

Funding (9 grants)

Impact

Open Access

Topics